EGFR mutation subtypes and response to immune checkpoint blockade treatment in non-small-cell lung cancer

BACKGROUND: Although EGFR mutant tumors exhibit low response rates to immune checkpoint blockade overall, some EGFR mutant tumors do respond to these therapies; however, there is a lack of understanding of the characteristics of EGFR mutant lung tumors responsive to immune checkpoint blockade. PATIE...

Descripción completa

Detalles Bibliográficos
Autores principales: Hastings, K, Yu, H A, Wei, W, Sanchez-Vega, F, DeVeaux, M, Choi, J, Rizvi, H, Lisberg, A, Truini, A, Lydon, C A, Liu, Z, Henick, B S, Wurtz, A, Cai, G, Plodkowski, A J, Long, N M, Halpenny, D F, Killam, J, Oliva, I, Schultz, N, Riely, G J, Arcila, M E, Ladanyi, M, Zelterman, D, Herbst, R S, Goldberg, S B, Awad, M M, Garon, E B, Gettinger, S, Hellmann, M D, Politi, K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683857/
https://www.ncbi.nlm.nih.gov/pubmed/31086949
http://dx.doi.org/10.1093/annonc/mdz141

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683857/
https://www.ncbi.nlm.nih.gov/pubmed/31086949
http://dx.doi.org/10.1093/annonc/mdz141

Ejemplares similares